WASHINGTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally recognized leader in investor protection, announces that investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in the company’s September 2024 initial public offering may seek to lead a federal securities class action. The deadline to move for appointment as lead plaintiff is June 16, 2025. [Click here for information about joining the class action] If you’d like to discuss this matter or your righ ...

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration state ...

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement a ...

文章核心观点 - Zenas BioPharma在2024年9月上市后因招股书误导投资者引发证券集体诉讼，投资者可在2025年6月16日前申请成为首席原告 [1][2][5] 公司情况 - Zenas BioPharma于2024年9月上市，首发股价17美元，后因招股书夸大资金持续时间致股价下跌近49%，2025年4月15日收盘价8.72美元 [1][5] - 诉讼指控该公司在IPO注册材料中夸大资金可维持运营时长，原称24个月，2024年11月SEC文件减至12个月 [5] 诉讼相关 - 科恩·米尔斯坦律师事务所呼吁IPO期间购买股票的投资者考虑加入诉讼并申请成为首席原告，申请截止日期为2025年6月16日 [2][9] - 联邦集体诉讼已在美国马萨诸塞州区联邦地方法院提起，购买IPO相关股票的投资者可申请成为首席原告，虽非必要但可影响案件策略和结果 [6] 律所情况 - 科恩·米尔斯坦是知名证券法律事务所，在高调投资者案件中表现出色，有超100名律师分布在8个办公室，曾在富国银行证券诉讼中获10亿美元赔偿 [7] - 该律所证券诉讼业务和多位证券诉讼律师被行业贸易出版物评为全国最佳之一 [8]

文章核心观点 - 格罗斯律师事务所通知泽纳斯生物制药公司股东参与集体诉讼，指控被告在特定时期发布虚假误导声明，股东可登记参与，申请首席原告截止日期为2025年6月16日 [1][4][5] 分组1：诉讼相关信息 - 鼓励在特定时期购买泽纳斯生物制药公司股票的股东联系律所，申请首席原告并非参与赔偿的必要条件 [1] - 诉讼代表在2024年9月公司首次公开募股相关登记声明和招股说明书下购买或获得公司证券的人 [3] - 指控被告在集体诉讼期间发布重大虚假或误导性声明，未披露公司夸大运营资金时长，公开声明虚假误导且准备疏忽 [4] 分组2：时间及流程 - 申请首席原告的截止日期为2025年6月16日，股东应尽快登记参与集体诉讼 [5] - 登记后将加入投资组合监控软件，获取案件进展更新，参与案件无成本和义务 [5] 分组3：律所介绍 - 格罗斯律师事务所是全国知名集体诉讼律所，使命是保护因欺诈等受损投资者权益，确保公司合规经营，为因虚假声明受损投资者寻求赔偿 [6] 分组4：联系方式 - 律所地址为纽约西38街15号12楼，邮箱为dg@securitiesclasslaw.com，电话为(646) 453 - 8903 [7] - 登记链接为https://securitiesclasslaw.com/securities/zenas - biopharma - inc - loss - submission - form/?id = 146203&from = 3 [3][5]

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=146175&from=4CLASS PERIOD: This lawsuit ...

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a “clinical stage global biopharmaceutical company committed to being a leader in the development an ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas’ registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [Y ...

WASHINGTON, April 29, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally prominent securities litigation firm, announces that retail and institutional investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the company's September 2024 initial public offering remain eligible to seek appointment as lead plaintiff in a securities class action lawsuit. The deadline to move for lead plaintiff is June 16, 2025. [Click here for information about j ...